The hybrid structure maintains PARP enzyme blocking activity while introducing DNA-alkylating damage to create a dual action mechanism which targets both PARP trapping and direct DNA damage to enhance cancer cell killing in drug-resistant tumors. This evidence concerns the gene PARP1 and cancer.